Delivery Order HHSO100201300010I-HHSO10033001T
Award Date 11/2/15
Potential Completion Date 9/30/21
Potential Value $45M
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Pine Brook, Montville, NJ, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The federal contract award HHSO100201000026C was issued by the Department of Health and Human Services (HHS) to Elusys Therapeutics Inc., a for-profit biomedical company, for advanced biomedical research and development. The $138,258,201.80 cost-plus-fixed-fee contract has an ultimate completion date of September 30, 2018. The contract is not designated as a set-aside. Elusys Therapeutics Inc. specializes in developing biomedical products and services, with a focus on advanced technology. The...
- This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services (HHS), to Elusys Therapeutics Inc. The contract, valued at $13,853,653.00, is for biomedical research and development services, ranging from basic to advanced capabilities. The contract is a Definitive Contract with a Cost No Fee pricing type, and does not have a set-aside designation. The period of performance runs from September 28,...
- This is a firm fixed price delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency under the Department of Health and Human Services (HHS), to Emergent Manufacturing Operations Baltimore LLC, a for-profit manufacturer of medical countermeasures. The $196,434,000 award is for the provision of anthrax antitoxins to treat inhalational anthrax, under the agency's medical countermeasures development and procurement program. The...
- This is a $40,360,613.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Hawaii Biotech, Inc. (HBI) to develop a small molecule drug anti-toxin therapeutic to treat anthrax in humans. The contract is not set aside for any specific business type. Key subcontractors include Labcorp Early Development Laboratories Inc. for pharmacokinetics research, Patheon API Services, Inc. for contract manufacturing,...
- This is a $3,044,549.00 fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for biomedical research and development work, with a period of performance ending on March 31, 2010. No set-aside designations were used. Resilience Government Services, a technology-focused biomanufacturing company, has...
- This is a $299,999.66 firm-fixed-price delivery order contract awarded by the Defense Health Agency (DHA) to Eitr Biologics, Inc., a for-profit biotechnology company. The contract is for the development of novel nanotherapeutics to combat viral infections and other biological threats, with a performance period through June 2026. Eitr Biologics has previously received multiple federal contract awards and grants from agencies like the Centers for Disease Control and Prevention (CDC) and the...
- This is a $6,821,012.21 Cost Plus Fixed Fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for the development of a broad spectrum monoclonal antibody-based therapeutic for botulism, a biological threat. The contract has no set-aside designation and the ultimate completion date is September...
- This is a $979,538.00 Firm Fixed Price Delivery Order contract awarded to Altimmune, Inc., a for-profit organization, by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response. The contract, which was not set aside, is for the development of vaccine formulations effective against NIAID priority pathogens, evaluation of clone generation and stability, biodefense vaccine enhancement, and general biomedical research. Altimmune, Inc....
- This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Biodefense Operations Lansing LLC, a for-profit manufacturer of medical countermeasures. The $1,174,464,339.10 firm fixed-price contract is for the production of BioThrax, the only FDA-licensed vaccine for the prevention of anthrax disease, which is a critical component of the U.S. government's strategic national stockpile. The...
- <p>This is a Cost Plus Fixed Fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Altimmune, Inc. for the development of a single-dose intranasal vaccine for post-exposure prophylaxis of inhalation anthrax. The award has a ceiling value of $135,880,962.00 and a period of performance through December 31, 2021. The contract was awarded on July 27, 2016 and does not have a set-aside designation.</p>